ABIVAX Société Anonyme (EPA:ABVX)
122.90
+0.30 (0.24%)
Jul 10, 2026, 5:35 PM CET
ABIVAX Société Anonyme Revenue
ABIVAX Société Anonyme had revenue of 1.34M EUR in the quarter ending March 31, 2026, with 35.21% growth. This brings the company's revenue in the last twelve months to 4.92M, down -59.82% year-over-year. In the year 2025, ABIVAX Société Anonyme had annual revenue of 4.57M, down -63.22%.
Revenue (ttm)
4.92M
Revenue Growth
-59.82%
P/S Ratio
2,148.01
Revenue / Employee
61.50K
Employees
80
Market Cap
10.57B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.57M | -7.86M | -63.22% |
| Dec 31, 2024 | 12.43M | 7.85M | 171.67% |
| Dec 31, 2023 | 4.57M | 69.00K | 1.53% |
| Dec 31, 2022 | 4.51M | 302.00K | 7.19% |
| Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 156.33M |
| Genfit | 70.85M |
| Cellectis | 65.14M |
| Nanobiotix | 32.59M |
| MedinCell | 24.28M |
| Innate Pharma | 9.01M |
| Transgene | 7.21M |
| Inventiva | 6.76M |
ABIVAX Société Anonyme News
- 15 hours ago - Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC - CNBC
- 1 day ago - Abivax price target raised to $175 from $165 at Piper Sandler - TheFly
- 3 days ago - Abivax: Wall Street Catches Up to the Data - MarketBeat
- 4 days ago - Abivax Announces Closing of $920 Million Public Offering - GlobeNewsWire
- 7 days ago - European Markets Rise to Record Highs Amid Optimism; Abivax SA (ABVX) Surges - GuruFocus
- 8 days ago - Abivax price target raised to $155 from $135 at Truist - TheFly
- 8 days ago - Abivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheet - WSJ
- 8 days ago - Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M) - GlobeNewsWire